Related Experiment Video
Updated: Mar 31, 2026
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Biophysical Characterization of Recurrent ErbB2 Missense Mutations Reveals Alterations in Receptor Organization and
Tayde Gabriela Serrano Cano1, Atena Yasari2, Ingrid Hartl2
1Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Abstract:
The purpose of this study was to characterize three recurrent, cancer-associated missense mutations in ErbB2, R143Q, R678Q, and V842I, located in the extracellular, juxtamembrane and kinase domains, respectively, to determine how single amino acid substitutions affect receptor organization and dynamics. Using confocal microscopy, Förster resonance energy transfer (FRET) and fluorescence recovery after photobleaching (FRAP), we assessed homo- and heteroassociation, lateral diffusion and tyrosine phosphorylation of ErbB2 cancer-associated variants either alone or co-expressed with EGFR. The only individual biophysical property that differentiated the mutation-activated ErbB2 variants from the wild-type was an accelerated diffusion in the absence of EGFR coexpression. Correlative analysis of the biophysical properties of ErbB2 revealed that ErbB2-activating mutations, including the cancer-associated R143Q, R678Q and V842I mutations, may promote a pre-dimerized receptor state associated with accelerated lateral mobility, but without full-scale activation implied by the lack of growth factor-independent tyrosine phosphorylation. The faster mobility of mutation-activated ErbB2 contrasted with the EGF-induced slowing down of its lateral diffusion. In summary, single amino acid substitutions across ErbB2 domains may modulate receptor dynamics, organization, and responsiveness.
Insights
Cancer-associated ErbB2 mutations (R143Q, R678Q, V842I) accelerate receptor diffusion. These mutations may promote a pre-dimerized state, altering ErbB2 dynamics without full activation.
Area of Science:
- Biochemistry
- Molecular Biology
- Cell Biology
Background:
- ErbB2 is a receptor tyrosine kinase implicated in various cancers.
- Cancer-associated mutations in ErbB2 can alter its function and signaling.
- Understanding the biophysical properties of ErbB2 mutants is crucial for targeted therapies.
Purpose of the Study:
- To characterize three cancer-associated missense mutations (R143Q, R678Q, V842I) in ErbB2.
- To determine how these single amino acid substitutions affect ErbB2 receptor organization and dynamics.
- To investigate the impact of these mutations on ErbB2 homo- and heteroassociation with EGFR.
Main Methods:
- Confocal microscopy
- Förster resonance energy transfer (FRET)
- Fluorescence recovery after photobleaching (FRAP)
- Assessment of ErbB2 variants alone or co-expressed with EGFR
Main Results:
- Mutation-activated ErbB2 variants exhibited accelerated lateral diffusion compared to wild-type ErbB2, particularly without EGFR coexpression.
- ErbB2 mutations may promote a pre-dimerized receptor state associated with increased lateral mobility.
- Despite altered dynamics, mutations did not lead to growth factor-independent tyrosine phosphorylation, indicating incomplete activation.
- EGF stimulation induced a slowing of lateral diffusion for wild-type ErbB2, contrasting with the faster mobility of mutants.
Conclusions:
- Single amino acid substitutions in ErbB2 domains can modulate receptor dynamics and organization.
- Cancer-associated ErbB2 mutations may pre-dispose the receptor to a more mobile, potentially pre-dimerized state.
- These dynamic alterations occur independently of full receptor activation, suggesting complex regulatory mechanisms.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:38Mitogens and the Cell Cycle